PRF Technologies Ltd. (PRFX)
NasdaqCM: PRFX
· Real-Time Price · USD
1.02
-0.01 (-0.97%)
At close: Aug 13, 2026, 1:56 PM
PRF Technologies Ltd. (PRFX) Stock Price, Analysis & Data
-0.97% (1D)
| Bid | 0.79 |
| Market Cap | 3.12M |
| Revenue (ttm) | 17K |
| Net Income (ttm) | -4.84M |
| Beta | 1.04 |
| EPS (ttm) | -7.47 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.08 |
| P/B (ttm) | 0.10 |
| P/S (ttm) | 183.40 |
| Earnings Date | n/a |
| Ask | 1.3 |
| Volume | 5,202,367 |
| Avg. Volume (20D) | 2,584,661 |
| Open | 1.03 |
| Previous Close | 1.03 |
| Day's Range | 1.01 - 1.11 |
| 52-Week Range | 0.97 - 17.95 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PRFX
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known...
Sector Healthcare
IPO Date Sep 1, 2020
Employees 6
Stock Exchange NasdaqCM
Ticker Symbol PRFX
Website https://www.painreform.com
Financial Performance
In 2025, PRF's revenue was 17K, an increase of undefined% compared to the previous year's 0. Earnings were -5.02M, a decrease of -65.57%.
Financial StatementsEarnings Surprise
PRF has released their quarterly earnings on Aug 15, 2024:
